Edesa Biotech (EDSA) Competitors $2.18 -0.02 (-0.91%) Closing price 07/15/2025 03:57 PM EasternExtended Trading$2.14 -0.04 (-1.79%) As of 07/15/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. NRXP, VTGN, UNCY, ICCC, CNTX, SNTI, ANL, IFRX, KRON, and AVTXShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include NRx Pharmaceuticals (NRXP), VistaGen Therapeutics (VTGN), Unicycive Therapeutics (UNCY), ImmuCell (ICCC), Context Therapeutics (CNTX), Senti Biosciences (SNTI), Adlai Nortye (ANL), InflaRx (IFRX), Kronos Bio (KRON), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors NRx Pharmaceuticals VistaGen Therapeutics Unicycive Therapeutics ImmuCell Context Therapeutics Senti Biosciences Adlai Nortye InflaRx Kronos Bio Avalo Therapeutics Edesa Biotech (NASDAQ:EDSA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Does the media refer more to EDSA or NRXP? In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.28 beat NRx Pharmaceuticals' score of 0.90 indicating that Edesa Biotech is being referred to more favorably in the media. Company Overall Sentiment Edesa Biotech Positive NRx Pharmaceuticals Positive Which has preferable valuation and earnings, EDSA or NRXP? NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$6.17M-$1.59-1.37NRx PharmaceuticalsN/AN/A-$25.13M-$2.01-1.55 Is EDSA or NRXP more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -187.01% -78.72% NRx Pharmaceuticals N/A N/A -355.00% Which has more volatility & risk, EDSA or NRXP? Edesa Biotech has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Do insiders & institutionals believe in EDSA or NRXP? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 22.6% of Edesa Biotech shares are held by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer EDSA or NRXP? Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 129.36%. NRx Pharmaceuticals has a consensus price target of $28.50, indicating a potential upside of 816.40%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryEdesa Biotech beats NRx Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.45M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-1.3720.2228.5719.58Price / SalesN/A291.25423.3093.84Price / CashN/A43.1536.0257.93Price / Book3.577.568.135.54Net Income-$6.17M-$55.11M$3.24B$257.73M7 Day Performance3.32%3.81%0.16%-0.08%1 Month Performance5.83%11.60%5.95%8.09%1 Year Performance-54.30%-2.11%26.09%13.02% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech2.2459 of 5 stars$2.18-0.9%$5.00+129.4%-48.5%$15.45MN/A-1.3720Positive NewsNRXPNRx Pharmaceuticals2.7392 of 5 stars$3.37-0.3%$28.50+745.7%+30.1%$58.44MN/A-1.682VTGNVistaGen Therapeutics1.0976 of 5 stars$2.21+10.5%N/A-42.5%$58.31M$490K-1.3340Positive NewsHigh Trading VolumeUNCYUnicycive Therapeutics2.9767 of 5 stars$4.69+2.0%$60.00+1,179.3%-7.4%$58.15MN/A-0.929High Trading VolumeICCCImmuCell0.2387 of 5 stars$6.53+2.2%N/A+47.6%$57.79M$26.49M-93.2770Positive NewsGap DownCNTXContext Therapeutics3.3186 of 5 stars$0.65+1.0%$5.50+750.2%-66.6%$57.43MN/A-2.097Positive NewsSNTISenti Biosciences2.2957 of 5 stars$2.21+0.5%$8.50+284.6%-40.3%$57.38MN/A-0.204Analyst UpgradeANLAdlai Nortye2.1024 of 5 stars$1.42-5.3%$9.00+533.8%-55.0%$55.35M$5M0.00127High Trading VolumeIFRXInflaRx2.732 of 5 stars$0.82+2.2%$6.60+704.9%-51.0%$53.87M$180K-1.0060Gap DownHigh Trading VolumeKRONKronos Bio2.7954 of 5 stars$0.88+1.5%$1.63+84.7%-38.9%$53.72M$9.85M-0.82100AVTXAvalo Therapeutics3.1258 of 5 stars$4.75-4.2%$30.00+531.6%-60.8%$53.71M$440K0.0040 Related Companies and Tools Related Companies NRXP Competitors VTGN Competitors UNCY Competitors ICCC Competitors CNTX Competitors SNTI Competitors ANL Competitors IFRX Competitors KRON Competitors AVTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDSA Stock Alerts